Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
  • A61K47/544—Phospholipids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
  • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
  • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
  • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Liposomes
  • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
  • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Definitions

• Molecular biologists have identified the chromosomal defects in a large number of human hereditary diseases, raising the prospects for cures using gene therapy.
• This emerging branch of medicine aims to correct genetic defects by transferring cloned and functionally active genes into the afflicted cells.
• Several systems and polymers suitable for the delivery of polynucleotides are known in the art.
• gene therapy may be useful to deliver therapeutic genes to treat various acquired and infectious diseases, autoimmune diseases and cancer.
• the invention comprises a method of stabilizing polynucleotide complexes by adding a cryoprotectant compound and lyophilizing the resulting formulation.
• Cryoprotectant compounds comprise carbohydrates, preferably lactose and sucrose, but also glucose, maltodextrins, mannitol, sorbitol, trehalose, and others. Betaines prolines, and other amino acids may also be useful.
• the invention comprises DNA complexes cryoprotected with lactose at concentrations of about 1.25% to about 10% (w/vol). Conventional buffers may also be added to the mixture.
• the invention also comprises the lyophilized mixtures.
• the lyophilized formulations may be stored for extended periods of time and then rehydrated prior to use.
• the lyophilized formulations may be milled or sieved into a dry powder formulation which may be used to deliver the polynucleotide complex. Once the powder contacts the desired tissue, it rehydrates, allowing delivery of the polynucleotide complex.
• a dry powder formulation is used to induce genetic modification of a patient's lung tissue.
• FIG. 1 shows the effect of rehydration on the particle size distribution of lipid-polynucleotide complexes at varying concentrations of mannitol and lactose.
• FIG. 2 compares the particle size distribution of lipid- polynucleotide complexes before lyophilization and after rehydration with and without cryoprotectant.
• FIG. 3 shows the particle size distribution for various lipid- polynucleotide complexes before and after lyophilization.
• FIG. 4 illustrates the effect of cryoprotectant on the zeta potential of lipid-polynucleotide complexes.
• FIG. 5 is a graphical representation of gel electrophoresis results indicating the effect of lyophillization on complexation between lipid and polynucleotide.
• FIGs. 6 and 7 show dose response curves of transfection efficiencycompannglyophillized and non-lyophillized lipid-polynucleotide complexes.
• FIGs. 8-10 show the effect of lyophilization on transfection efficiency for lipid-polynucleotide complexes.
• FIGs. 1 1 -13 illustrate the effect of time on the transfection efficiency of lyophillized lipid-polynucleotide complexes.
• FIG. 14 illustrates the effect of time on the transfection efficiency of rehydrated lipid-polynucleotide complexes.
• FIG. 15 illustrates transfection using lyophilized dendrimer- polynucleotide complexes.
• FIGs. 16-17 illustrate transfection using other lipid-polynucleotide complexes.
• FIG. 18 shows expression of genetic information transferred using a dry powder formulation of a lyophilized polynucleotide complex.
• FIG. 19-31 show various cationic lipids useful in forming lipid:polynucleotide complexes for lyophilization.
• FIG. 32 shows predicted deposition sites in the respiratory tract for various size particles.
• the invention comprises stabilizing polynucleotide complexes by adding a cryoprotectant and lyophilizing the resulting mixture.
• Cryoprotectant compounds comprise carbohydrates, preferably lactose and sucrose, but also glucose, maltodextrins, mannitol, sorbitol, trehalose, and others. It is believed the hydroxyl groups of the carbohydrates form hydrogen bonds with the polynucleotide complexes, displacing water and stabilizing the complexes.
• Useful ranges of cryprotectant range from about 1.25% to about 10%, and particularly from 5-10%.
• Other suitable cryoprotectants include amino acids such as betaines and prolines that exhibit this hydrogen bonding stabilization effect.
• polynucleotide complexes may be stabilized with the lyophillization techniques of this invention.
• the polynucleotide may be a single-stranded DNA or RNA, or a double-stranded DNA or DNA- RNA hybrid. Triple- or quadruple-stranded polynucleotides with therapeutic value are also contemplated to be within the scope of this invention.
• double-stranded DNA include structural genes, genes including operator control and termination regions, and self- replicating systems such as plasmid DNA, among others.
• Single-stranded polynucleotides or "therapeutic strands” include antisense polynucleotides (DNA and RNA), ribozymes and triplex-forming oligonucleotides.
• the therapeutic strand preferably has as some or all of its nucleotide linkages stabilized as non-phosphodiester linkages. Such linkages include, for example, phosphorothioate, phosphorodithioate, phosphoroselenate, or O-alkyl phosphotriester linkages wherein the alkyl group is methyl or ethyl, among others.
• the complementary or "linker strand” it may be preferable to prepare the complementary or "linker strand" to the therapeutic strand as part of the administered composition.
• the linker strand is usually synthesized with a phosphodiester linkage so that it is degraded after entering the cell.
• the "linker strand” may be a separate strand, or it may be covalently attached to or a mere extension of the therapeutic strand so that the therapeutic strand essentially doubles back and hybridizes to itself.
• the linker strand may have a number of arms that are complementary so that it hybridizes to a plurality of polynucleotide strands.
• the linker strand may also have functionalities on the 3' or 5' end or on the carbohydrate or backbone of the linker that serve as functional components to enhance the activity of the therapeutic strand.
• the phosphodiester linker strand may contain a targeting ligand such as a folate derivative that permits recognition and internalization into the target cells. If the linker is attached to its complementary therapeutic strand that is composed of degradation-resistant linkages, the duplex would be internalized. Once inside the cell, the linker will be degraded, thereby releasing the therapeutic strand. In this manner, the therapeutic strand will have no additional functionalities attached and its function will not be impeded by non-essential moieties.
• This strategy can be applied to any antisense, ribozyme or triplex-forming polynucleotide and it is used to deliver anti-viral, anti-bacterial, anti- neoplastic, anti-inflammatory, anti-proliferative, anti-receptorblocking or anti-transport polynucleotides, and the like.
• a separate linker strand may be synthesized to have the direct complementary sequence to the therapeutic strand and hybridize to it in a one-on-one fashion.
• the linker strand may be constructed so that the 5' region of the linker strand hybridizes to the 5' region of the therapeutic strand, and the 3' region of the linker strand hybridizes to the 3' region of the therapeutic strand to form a concatenate of the following structure. 5'
• This concatenate has the advantage that the apparent molecular weight of the therapeutic nucleic acids is increased and its pharmacokinetic properties and targeting ligand:therapeutic oligonucleotide ratio can be adjusted to achieve the optimal therapeutic effect.
• the linker strand may also be branched and able to hybridize to more than one copy of the polynucleotide.
• Other strategies may be employed to deliver different polynucleotides concomitantly. This would allow multiple genes to be delivered as part of a single treatment regimen.
• the polynucleotide complex may comprise naked polynucleotide such as plasmid DNA, multiple copies of the polynucleotide or different polynucleotides, or may comprise a polynucleotide associated with a peptide, a lipid including cationic lipids, a liposome or lipidic particle, a polycation such as polylysine, a branched, three-dimensional polycation such as a dendrimer, a carbohydrate or other compounds that facilitate gene transfer.
• Examples of useful polynucleotide compositions are found in U.S. Patent Applications Ser. No. 08/092,200, filed July 14, 1992, and Serial No. 07/913,669, filed July 14, 1993, which are hereby incorporated in their entirety by reference thereto.
• DOTMA dioleoyl phosphatidylethanolamine
• Cryoprotectant, lipid and plasmid DNA containing a CMV promoter and a ?-galactosidase (CMV- gal) or chloroamphenicol acetyl transferase (CMV-CAT) reporter gene were mixed together under defined conditions to produce a 1 : 10:X (w:w:w) of pDNA/lipid/cryoprotectant formulation at a constant pDNA concentration of 250 ⁇ g/ml in a final volume of 1 ml, where X was 30, 100, 200, 250, 300, 500, 600, 750 and 100. This corresponds to a DNA:lipid charge ratio of 1 :2.
• the cryoprotectants used were mannitol and lactose.
• the formulations were lyophillized using a programmable tray dryer (FTS Systems) at a product eutectic temperature of -30°C.
• FTS Systems programmable tray dryer
• the lyophilized formulations were rehydrated at room temperature with water to a pDNA concentration of 250 g/ml.
• the physicochemical properties of the lipid-pDNA complexes was determined by particle size analysis (Coulter N4MD), doppler electrophoretic light scattering (Coulter Delsa 440) and 1 % agarose gel electrophoresis.
• FTS Systems programmable tray dryer
• HIG- 82 (rabbit synoviocytes), C 2 C 12 (mouse myoblasts) and HepG2 (human liver hepatoblastoma) cells were grown in F-12 Ham's, Dulbecco's Modified and in minimum essential Eagle's media (Gibco), respectively. All were supplemented with 10% fetal bovine serum (Gibco). Transfection was performed in the presence of serum containing media in 24- well plates at 40-60% cell density with 2 ⁇ g of pDNA per well. Cells were harvested and analyzed after 48 hours. A chemiluminescent reporter assay was performed according to TROPIX (Galacto-light ) specifications.
• TROPIX Galacto-light
• the percentage of yff-galactosidase (LacZ) positive cells was determined by Commasie Blue protein assay. Relative light units (RLU) per ⁇ g of total protein and percentage of LacZ positive cells were used to assess transfection efficiency.
• FIG. 1 shows the effect of rehydration on the particle size distribution of lipid-pDNA complexes at varying concentrations of mannitol and lactose.
• cryprotectant:lipid ratios of 40:1 to 100: 1 corresponding to 4% and 10% formulations
• complexes protected with lactose exhibit similar particle size distribution to non-lyophillized lipid- pDNA complexes.
• the complexes protected with mannitol exhibit larger particle size distributions.
• FIG. 2 shows that lipid-pDNA complexes lyophillized without a cryoprotectant aggregate while lipid-pDNA complexes protected with lactose or sucrose do not aggregate following rehydration and exhibit particles size distributions substantially the same as before lyophillization.
• FIG. 3 shows the particle size distribution before and after lyophillization for various lipid-pDNA complexes protected with 10% lactose. Lyophillization had little effect on particle size distribution regardless of the lipid composition or charge ratio.
• FIG. 4 compares the zeta potential of lipid-pDNA complexes in the presence and absence of cryoprotectant.
• the presence of 10% lactose had substantially no effect on the zeta potential, except at a charge ratio of 1 :1 .
• FIG. 5 is a graphical representation of gel electrophoresis results comparing lipid-pDNA complexes before and after lyophillization. Migration of the bands was generally unaffected following lyophillization and rehydration. This indicates the complexation between the lipid and the pDNA was not affected by the addition of 10% lactose.
• FIGs. 6 and 7 show dose response curves of transfection efficiency comparing lyophillized and non-lyophillized lipid-pDNA complexes protected with 5% lactose, sucrose or glucose. At each pDNA concentration and for each cryoprotectant, transfection efficiency was either unaffected or improved by lyophillization.
• FIGs. 8-10 show the effect of lyophilization on transfection efficiency for lipid-pDNA complexes: FIG. 8 shows transfer of CMV-CAT at pDNA:DOTMA/DOPE ratios of 1 : 10 and 1 :6 in C 2 C 12 cells; FIG. 9 shows transfer of CMV- gal at pDNA:DOTMA/DOPE ratios of 1 : 10 and 1 :6 in C 2 C 12 cells; and FIG. 10 shows transfer of CMV- gal at pDNA:DOTM A/DOPE ratios of 1 : 10 and 1 :6 in HepG2 cells. In each case transfection efficiency was improved by lyophillization.
• FIGs. . 1 1-13 show the transfection efficiency of stored DDAB:DOPE-DNA lyophilized complexes prepared at various conditions. Storage of the lyophillized lipid-pDNA did not decrease the transfection efficiency and some cases activity increased. In contrast, FIG. 14 shows the effect of storage time on the activity of rehydrated lipid- pDNA complexes. Transfection efficiency fell over a two week period. This indicates the DNA compositions are stable only when in a lyophillized condition.
• Other useful DNA complexes may be prepared as follows:
• a gramicidin S-pDNA complex is formed with DNA encoding the luciferase gene.
• 20 ⁇ g of pDNA is diluted in 300 ⁇ of 30 mM Tris HCL pH 8.5 in a polystyrene tube.
• Gramicidin S is diluted in Tris HCL 30 mM ph
• a dendrimer-pDNA complex is formed with DNA encoding the luciferase gene.
• 6 ⁇ g of pDNA is diluted in 330 ⁇ of 10 mM Hepes pH 7.3 in a polystyrene tube.
• the polycation sixth generation starburst dendrimer (2 - 160 ⁇ g) is diluted in Tris HCL 170 of HBS and added dropwise to the DNA and then gently mixed. Lactose is added to a final concentration of 225 mM and the material placed in a vial.
• the formulation is frozen in a dry-ice ethanol bath and then lyophillized to produce a dry cake.
• the dry cake may be stored at 4°C and rehydrated to original volume.
• FIG. 15 shows expression in cells transfected using a ?-gal- dendrimer complex cryoprotected with lactose or sucrose and lyophilized at various temperatures.
• FIG. 16 illustrates transfection using lyophilized complexes of ?-gal associated with a 1 :2 molar ratio of dimethyldioctadecylammonium bromide [DDAB]:dioleoyl phosphatidylethanolamine [DOPE] at varied charge ratios and varied doses.
• the complexes were cryoprotected at a pDNA:lactose weight ratio of 1 : 15.
• FIG.17 shows transfection using lyophilized complexes of yff-gal associated with a 1:1 molar ratio of [DOTAP]:dioleoyl phosphatidylethanolamine [DOPE] lyophilized with various concentrations of sucrose and frozen at various temperatures.
• other cryoprotectants may be used at similar concentration to the above examples.
• the formulations can be lyophilized and then rehydrated in a lesser volume to concentrate polynucleotide complex.
• the formulations may also include buffers that can be removed during lyophillization allows concentration of the preparation and subsequent rehydration to isotonicity.
• Suitable volatile buffers include triethanolamine-acetate, triethanolamine-carbonate, ammonium acetate, ammonium carbonate and other at concentrations from about 0.01 M to about 2 M.
• a polynucleotide complex in a 1.25% sucrose solution and a 100 mM ammonium triethanolamine carbonate may be lyophilized and then rehydrated to 1 /8 the original volume, maintaining the isotonicity of the rehydrated solution and concentrating the polynucleotide complex 8-fold.
• Cationic lipids are useful in forming complexes to be cryoprotected and lyophilized.
• cationic lipids suitable for the practice of the invention include phosphatidylethanolamine [PE], dioleyloxy phosphatidylethanolamine [DOPE], n-[1-(2,3- dioleyloxy)propyl]-N,N,N-trimethylammonium chloride [DOTMA], dioleoylphosphatidylcholine [DOPC], 2,3-dioleyloxy-N-[2- (sperminecarboxyamido)ethyl]-N,N-dimethyl-1-propanaminium trif luoroacetate [DOSPA], [DOTAP], [DOGG], dimethyldioctadecylammonium bromide [DDAB], cety I d i methy lethy I ammo n i u m bromide [CDAB], cetyltrimethylethylammonium bromide [CTAB], monooleoyl-glycerol [MOG], 1,2 dimer
• a p-nitrophenyl oleinate ester was prepared by a standard method. This active ester coupled with octadecylamine to give N-octadecyl oleic amide. Reduction of this amid by lithium aluminum hydride formed N'- stearyl N-oleyl amine. A mixture of N-stearyl N-oleyl amine, N- butoxycarbonylglycine p-nitrophenyl ester, and triethylamine in dichloromethane was stirred at room temperature under argon for 24 h. The organic solution was extracted three times with 0.5 M sodium carbonate, followed by water, and then dried over sodium sulfate.
• N- t-butoxycarbonylglycine N'-stearyl - N'-oleyl
• This compound was deprotected by trifluoroacetic acid to give glycine (N'-stearyl - N'-oleyl) amide, which was then treated with tetra-t-butoxycarbonylspermine-5-carboxylic acid (prepared by the cyanoethylation of ornitine, followed by a hydrogenation and protection with Boc-on), dicyclohexylcarbodiimide and N-hudroxysuccinimide in dichloromethane in dark at room temperature under argon for 48 h.
• This compound was treated with trifluoroacetic acid (0.5 mi) at room temperature under argon for 10 min. The excess trifluoroacetic acid was removed under reduced pressure to give spermine-5-carboxy- ⁇ -alanine cholesteryl ester tetratrifluoroacetic acid salt as a white solid.
• FIG. 23 Produced in a manner similar to CAS, by substituting for the appropriate starting material.
• FIG. 25 Cyanoethylation of the ?-alanine with acrylnitrile in the presence of 1 ,4-diazabicyclo [2.2.2] octane at 90 °C for 15 h gave the N,N-bis(2- cyanoethyl)-3-aminopropionic acid.
• This compound was activated by chloroacetonitrile and triethylamine to form cyanomethyl N,N-bis (t-butoxycarbonyl-3-animoethyl)-3- aminopropionate.
• a solution of the cyanomethyl ester and cholesteryl ?-alanine ester in chloromethane was stirred in dark at room temperature under argon for 10 days. The solvent was removed under reduced pressure, and the residue was purified by a silica gel column using methanol-chloroform (1 :10) as eluant to yield the N,N-bis (t- butoxycarbonyl-3-aminoethyl)-3-aminopropionoyl /?-alanine cholesteryl ester.
• Carnitine ester lipids are synthesized by acylating the hydroxy group of L- carnitine by standard methods to create the monoacyl carnitine.
• the carboxy group of the carnitine is modified with a second acyl chain to make a phospholipid analog with a single quarternary ammonium cationic group.
• the other carnitine stereoisomers D- and D,L- are suitable, but the L-form is preferred.
• the acyl chains are between 2 and 30 carbons and may be saturated or unsaturated, with from 1 to 6 unsaturated groups in either the cis or trans configuration. The acyl chains may also contain iso forms.
• a preferred form comprises the oleoyl group, a chain 18 carbons long with a cis unsaturated bond at C 9 .
• This generic carnitine ester is shown in FIG. 27. Presently preferred carnitine esters follow. Stearyl carnitine ester
• FIG. 28 A solution of DL-carnitine hydrochloride (1.0 g, 5.05 mmol) and sodium hydroxide (0.303 g, 7.58 mmol) in ethanol (15 mi) was stirred at room temperature for 2 h. The formed white precipitate (NaCl) was removed by filtration, and the solvent was evaporated under reduced pressure to give a white solid, carnitine inner salt.
• L-SSCE L-Stearyl Stearoyl Carnitine Ester
• L-MMCE L-Myristyl myristoyi carnitine ester chloride
• Lyophillized polynucleotide complexes may be sieved or milled to produce dry powder formulations (DPF).
• the powder may be used to generate a powder aerosol for delivering the polynucleotide to the lung.
• a current limitation of aerosol delivery is that high concentrations of DNA must be used in order to achieve sufficient gene transfer. At these concentrations, the polynucleotide complexes aggregate.
• the DPF permits use of high concentrations of polynucleotide.
• the powder is diluted when dispersed into the lung so that risk of aggregation is minimized. Once in contact with the lung tissue, the powder will rehydrate and regain its activity.
• plasmid CMV-CAT DNA was complexed as described above with a DOTMA:DOPE lipid formulation at a ratio of 1 : 10 (w/w).
• naked pCMV-CAT may be cryoprotected.
• the cryoprotectant mannitol was added at pDNA:mannitol ratios of 1 :100 and 1 :500 (w/w).
• the formulations were lyophillized at a product eutect temperature of 30°C to form a dry cake and retained under vacuum. Control instillation formulations were rehydrated to provide physicochemical and transfective comparison to the DPFs.
• the lyophillized product was sieved using a brass U.S.A.
• exemplary pCMV-CAT concentrations for the DPFs are as follows: 1 :0: 100 (w/w/w) pDNA:lipid:mannitol - 1 .41 g/mg
• the DPFs were tested for in vivo activity by treating mice with the formulations and a Pharmatose control, harvesting the lung and trachea and assessing CAT expression. 10 mg of DPF were delivered via direct intratracheal injections using a Penn-Century Delivery device, resulting in approximately 50% delivery.
• FIG. 18 shows that the CMV-CAT DPF delivered at various doses resulted in CAT expression in the lung cells.
• DPFs were produced using a jet milled using a high speed shear mixer.
• a 1 : 10: 100 (w/w/w) pDNA/lipid/mannitol complex was jet milled at a grinding pressure of 130 psi and a feed rate of 40 mg/ml.
• the resulting powder had a nearly monodisperse particle size distribution of 80% at 3.2 - 3.8 pm as determined by laser light scattering. Electron microscopy revealed that many particles were ⁇ 1 pm. Jet milling at a grinding pressure of 80 psi and a feed rate of 700 mg/ml resulted in a nearly monodisperse particle size distribution of 80% at 3.7 - 4.8 pm. In comparison, a sieved DPF showed a slight increase in the percentage of particles ⁇ 10 pm. Prior to jet milling, the DPF was polydisperse with a particle size distribution of 80% at 5 -27 pm.
• DPFs may be used to deliver genes useful in the treatment of a lung disease.
• complexes formed with DNA encoding for cystic fibrosis transmembrane conductance regulator (CFTR) may be used to treat cystic fibrosis.
• CFTR cystic fibrosis transmembrane conductance regulator
• other lung diseases such as alpha-1 -antitrypsin deficiency, asthma, pulmonary embolism, adult respiratory distress syndrome, pulmonary hypertension, chronic obstructive pulmonary disease, lung cancer, pulmonary fibrosis, pulmonary microbial infections, pulmonary pseudomonas infections, pulmonary inflammatory disorders, chronic bronchitis, pulmonary viral infections, respiratory syncitial virus, lung tissue rejection, emphysema and pulmonary allergic disorders could be treated.
• the average particle size of the DPF is controlled to skew the deposition of the particles in desired region of the respiratory system.
• the deposition of particles is affected by a number of factors, including environmental conditions, particle characteristics, respiratory tract characteristics and breathing pattern characteristics, predictive models are possible.
• FIG. 32 shows the deposition fraction at various compartments of the respiratory tract for inhaled aerosols as a function of particle size.
• DPFs should generally have an average particle size of less than about 100 pm, preferably less than about 10 pm, and particularly preferably less than about 1 pm for treatment of the lung.
• DPFs are useful for the treatment of skin diseases.
• DPFs could be also be formulated as a pill for ingestion or as a suppository allowing for treatment of a wide range of internal or systemic conditions.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Dispersion Chemistry (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• Immunology (AREA)
• Otolaryngology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biotechnology (AREA)
• Nanotechnology (AREA)
• Botany (AREA)
• Pulmonology (AREA)
• General Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Saccharide Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (2)

Family

ID=23928143

Family Applications (2)

Family Applications After (1)

Country Status (5)

Families Citing this family (30)

Citations (4)

Family Cites Families (6)

• 1996
  • 1996-05-28 WO PCT/US1996/007866 patent/WO1996040265A1/en not_active Application Discontinuation
  • 1996-05-28 EP EP96916714A patent/EP0833667A4/de not_active Withdrawn
  • 1996-05-28 JP JP50079397A patent/JP2001516329A/ja not_active Ceased
  • 1996-05-28 EP EP20040000585 patent/EP1491217A1/de not_active Withdrawn
  • 1996-05-28 CA CA002223921A patent/CA2223921A1/en not_active Abandoned
  • 1996-05-28 AU AU59381/96A patent/AU707734B2/en not_active Withdrawn - After Issue

Patent Citations (4)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events